The B-cell lymphoma/leukemia 11A (BCL11A) gene was first identified in the rare t(2;14)(p16;q32.3) translocation in aggressive B-cell chronic lymphocytic leukemia and, together with REL, is a candidate for the 2p16 chromosomal amplifications in B-cell malignancies.
1 BCL11A encodes a Krü ppel zinc-finger transcription factor, and Evi9/Bcl11a/Ctip1 (mouse homologue of human BCL11A) has been shown to be essential for pre-B-cell development and thymocyte maturation. 2 There is evidence that Bcl11a, and hence human BCL11A, may not only encode a dominant proto-oncogene but also function as a non-autonomous T-cell tumor suppressor gene. 2 Alternative RNA splicing generates at least three BCL11A transcripts with restricted expression in bone marrow, lymphoid tissue and brain. BCL11A XL mRNA is the largest and the most abundant transcript. 1 We produced a novel monoclonal antibody, BCL11A/123, raised against BCL11A XL recombinant GST-BCL11A fusion protein (aa 637-835), which was used in a variety of immunolabeling and Western blotting techniques 3 to study BCL11A XL expression in a wide variety of normal and malignant human cells and tissues. The specificity of the antibody was confirmed using transfected COS cells expressing BCL11A S , BCL11A L , BCL11A XL or the highly homologous BCL11B protein ( Figure 1a and b and Supplementary Information).
BCL11A XL protein was detected in the nuclei of cells in the mantle zone, the majority of nuclei in the germinal centers and a subpopulation of cells in the interfollicular areas of tonsil and lymph node (Figure 1c ). Nuclear staining of the splenic marginal zone was also observed. Double immunolabeling studies demonstrated most of the BCL11A XL -positive cells in the tonsil to be of B-cell origin (Figure 1d ), whereas T cells ( Figure 1e ) and plasma cells ( Figure 1f ) were BCL11A XL -negative. Only rare BCL11A XL -positive cells were observed in the bone marrow and fetal thymus and these coexpressed either CD68 or CD79a antigen. Although high levels of BCL11A transcripts have been described in peripheral blood B cells (http://symatlas.gnf.org/), BCL11A XL protein expression was not detected in peripheral blood smears or purified CD20-positive B cells from normal subjects. Activation of purified CD20-positive B cells with Staphyloccus aureus and rIL-2 did, however, result in the induction of nuclear expression of BCL11A XL .
Of note was the appearance of scattered cells with very strongly labeled nuclei in the interfollicular areas of the tonsil and lymph node (Figure 1c, inset) . These cells were also labeled by all three commercially available anti-Ctip1/Bcl11a antibodies (Abcam, Cambridge, UK) but not with the anti-Bcl11b-specific polyclonal antibody. These distinctive cells were negative for CD20 (Figure 1g , left inset) and CD3 (Figure 1g , right inset), CD11c, CD31, CD32, CD34 and CD79a but expressed CD68 (Figure 1h ) and CD4. Eighty-five to 95% of these BCL11A XL -positive cells also coexpressed the plasmacytoid dendritic cell (pDC) marker CD123 ( Figure 1i ). Although high levels of BCL11A XL transcripts have been reported in pDCs (http://symatlas.gnf.org/), this is the first report of BCL11A XL protein expression in human pDCs. Additional support for BCL11A expression in this subset of dendritic cells is provided by the recent report of Bcl11a transcripts in murine pDCs. 4 Nuclear labeling for BCL11A XL was observed in a subpopulation of cells in thymus. Although the majority of the medullary BCL11A XL -positive cells were CD20-positive B cells, scattered CD20-negative cells with strongly stained nuclei, reminiscent of the pDCs described above, were also observed ( Figure 1j ). BCL11A XL protein was detected in a subpopulation of CD3-positive thymic T cells (Figure 1k ).
With the exception of weak nuclear labeling of neurons in the adult cerebral cortex, strong labeling of tonsillar epithelium and a subpopulation of epithelial cells in the gut and thymic cortex (Figure 1k The results obtained from a study of a wide range of hematological tumors present on tumor microarrays (TMA) are summarized in Table 1 . Nuclear BCL11A XL expression was observed in a wide variety of B-cell tumors but was undetectable in the myeloma cases studied and in Reed-Sternberg cells in the majority of cases of Hodgkin's lymphoma. With the exception of only 2/5 cases of T-cell acute lymphoblastic lymphoma/leukemia (T-ALL) and 1/3 cases of natural killer cell lymphoma, BCL11A XL protein was not found in the T-cell tumors studied.
An immunolabeling study on a TMA of 107 cases of previously untreated diffuse large B-cell lymphoma (DLBCL) obtained from the British Columbia Cancer Agency 5 demonstrated BCL11A XL expression in 82% (45/55) and 70% (35/50) of cases immunophenotyped previously as being of either germinal center (GC) or non-germinal center (ABC) origin, respectively. This lack of differential expression of BCL11A XL between GCand ABC-derived tumors is in keeping with a recent report in which BCL11A transcripts were not influenced by 2p14-p16 gains. 6 There was, however, correlation between BCL6 and BCL11A XL protein expression, with 79% of BCL6-positive cases also expressing BCL11A XL (P40.010), but no correlation was observed with BCL2 (P40.86).
Although no relationship between BCL11A XL expression and failure-free survival was found, there was a tendency towards decreased survival in patients whose tumors lacked BCL11A XL (P40.1) (Figure 1l ). Further analyses of protein expression data may reveal additional correlations between BCL11A XL and other tumor-associated molecules, such as FOXP1, which are of prognostic significance. 5 The observation that BCL11A XL protein is absent in normal plasma cells, 5/6 plasma cell-derived lines and the myeloma cases studied suggests that downregulation of BCL11A XL might be a requirement for plasmacytic differentiation. Indeed previous cDNA microarray studies have identified BCL11A as one of the target genes repressed by the Blimp-1 transcription factor.
7
BCL11A XL was detected in the T-ALL-derived Jurkat, MKB1 and CEM T-cell lines and a small subpopulation of the myeloid U937 cells. Liu et al. 2 reported Bcl11A expression to be important not only for B-cell differentiation but also for T-cell maturation and the development of T-cell leukemia. The presence of BCL11A XL protein in normal and malignant T cells is therefore not inconsistent with these findings. Indeed, the presence of BCL11A XL in the nuclei of thymic epithelial cells may be of importance as interactions between the thymocyte and epithelial cell compartments play a vital role in T-cell development and selection. 8 In conclusion, this is the first description of BCL11A XL protein distribution in both normal and neoplastic cells. Besides representing a transcription factor that is differentially expressed in B-cell development, BCL11A XL is an additional marker for pDCs. The antibody described here represents an important tool for ascertaining the function of BCL11A XL not only in normal cellular development but also the role of BCL11A and/or its interacting proteins in tumorigenesis.
Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects Among the biological prognostic factors so far identified in chronic lymphocytic leukemia (CLL), mutation or deletion of the p53 gene encoded at 17p13 is the most powerful predictor of short survival. p53 is a transcription factor that is activated by DNA damage and coordinates the cellular response to such damage by triggering apoptosis or cell-cycle arrest. In doing so, it fulfils an important function in regulating cell growth and survival in the face of cellular stresses and plays a pivotal role in Table 1 Expression of BCL11A XL protein in lymphoid neoplasms Letter to the Editor
